Company / Net Income
Xenon Pharmaceuticals Inc. Net Income History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Net Income
-$345.9M
FY2025
5-year range
-$345.9M / -$78.9M
FY2021-FY2025
Trend
-47.6%
vs FY2024
Sector context
#184 of 216
Health Care
What the data says
Xenon Pharmaceuticals Inc.'s net income of -$346M is lower than 85% of companies in the Health Care sector (FY2025). Net Income has declined for 5 consecutive years, from -$29M in FY2020 to -$346M in FY2025.
Based on SEC 10-K filings.
-$346M in FY2025.
Declined from -$182M to -$346M over the past 2 years.
Health Care sector context is included.
Net Income over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 15% in Health CareTop 85% of 216This company -$345.9M Sector average $454.3M
▼
-176.1% below sector average
Key checks
Key Insights
- Xenon Pharmaceuticals Inc.'s net income has declined for 5 consecutive years.
- In FY2025, net income decreased 47.6% year-over-year.
- Ranks #184 out of 216 companies in the Health Care sector.
- Peak net income was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.51 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Net IncomeValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$345.9M | -47.6% |
| FY2024 | -$234.3M | -28.5% |
| FY2023 | -$182.4M | -45.5% |
| FY2022 | -$125.4M | -58.9% |
| FY2021 | -$78.9M | -173.5% |
| FY2020 | -$28.8M | +30.7% |
| FY2019 | -$41.6M | -20.6% |
| FY2018 | -$34.5M | -119.0% |
| FY2017 | -$15.8M | +31.5% |
| FY2016 | -$23.0M | -46.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026